The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic
Open accessAbstract
Targeting kinases is central to drug-based cancer therapy but remains challenging because the drugs often lack specificity, which may cause toxic side effects. Modulating side effects is difficult because kinases are evolutionarily and hence structurally related. The lack of specificity of the anticancer drug imatinib enables it to be used to treat chronic myeloid leukemia, where its target is the Bcr-Abl kinase, as well as a proportion of gastrointestinal stromal tumors (GISTs), where its target is the C-Kit kinase. However, imatinib also has cardiotoxic effects traceable to its impact on the C-Abl kinase. Motivated by this finding, we made a modification to imatinib that hampers Bcr-Abl inhibition; refocuses the impact on the C-Kit kinase; and promotes inhibition of an additional target, JNK, a change that is required to reinforce prevention of cardiotoxicity. We established the molecular blueprint for target discrimination in vitro using spectrophotometric and colorimetric assays and through a phage-displayed kinase screening library. We demonstrated controlled inhibitory impact on C-Kit kinase in human cell lines and established the therapeutic impact of the engineered compound in a novel GIST mouse model, revealing a marked reduction of cardiotoxicity. These findings identify the reengineered imatinib as an agent to treat GISTs with curbed side effects and reveal a bottom-up approach to control drug specificity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Thaker, P. H., Han, L. Y., Kamat, A. A., Arevalo, J. M., Takahashi, R., Lu, C., Jennings, N. B., Armaiz-Pena, G., Bankson, J. A., Ravoori, M., et al. (2006) · Nature Medicine · doi:10.1038/nm1447 · Cited by 1,320
Self-citationEstey, E. H., Giles, F. J., Kantarjian, H., O’Brien, S., Cortes, J., Freireich, E. J., Lopez-Berestein, G., & Keating, M. (1999) · Blood · doi:10.1182/blood.v94.7.2230.419k05_2230_2235 · Cited by 105
Self-citation
Cited by
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Moslehi, J. J., & Deininger, M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4718 · Cited by 443
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT
Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007258 · Cited by 421
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
Chen, M. H., Kerkelä, R., & Force, T. (2008) · Circulation · doi:10.1161/circulationaha.108.776831 · Cited by 379
Rational Approaches to Improving Selectivity in Drug Design
Huggins, D. J., Sherman, W., & Tidor, B. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2010332 · Cited by 367
Metadata
- Authors
- Fernández, A., Sanguino, A., Peng, Z., Ozturk, E., Chen, J., Crespo, A., Wulf, S., Shavrin, A., Qin, C., Ma, J., Trent, J., Lin, Y., Han, H.-D., Mangala, L. S., Bankson, J. A., Gelovani, J., Samarel, A., Bornmann, W., Sood, A. K., & Lopez-Berestein, G.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-12-03
- Volume
- 117
- Issue
- 12
- Pages
- 4044-4054
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2102050170
- Cited by
- 158
- References
- 2
- FWCI
- 17.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. https://app.cochat.ai/papers/10.1172/jci32373
- The paper
- Fernández, A., Sanguino, A., Peng, Z., Ozturk, E., Chen, J., Crespo, A., Wulf, S., Shavrin, A., Qin, C., Ma, J., Trent, J., Lin, Y., Han, H.-D., Mangala, L. S., Bankson, J. A., Gelovani, J., Samarel, A., Bornmann, W., Sood, A. K., & Lopez-Berestein, G. (2007). An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. Journal of Clinical Investigation. https://doi.org/10.1172/jci32373
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.